Engflag

Levedia

Quick links to important sections

Levedia

There is no image.

Method of action: Anticonvulsant, Antiepileptic

Treatment option: Seizure, Convulsions, Epilepsy, Juvenile Myoclonic Epilepsy

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Levedia

What Type of Medicine is Levedia (Levetiracetam)?

Levedia is a prescription-only medicine (POM) whose active ingredient is Levetiracetam (INN). The drug is formally classified within the pharmacological class of antiepileptic drugs (AEDs), utilized to help manage seizure disorders. Levetiracetam is an anticonvulsant that targets abnormal excitability in the brain, as the medicine is designed to regulate neural activity.

Levetiracetam is a synthetic compound chemically identified as a pyrrolidine derivative and is classified as a second-generation AED. Its categorization as a second-generation agent is based on its specific mechanism, which distinguishes it from older drug classes. Levedia is a brand associated with this formulation, which is available for both adult and pediatric patients, unlike medications restricted solely to adult populations.

Composition, Forms, and General Purpose

The medication is supplied as a single-agent product, with Levetiracetam as the sole active component. It is formulated in multiple dosage forms, including film-coated tablets and a liquid oral solution, along with an intravenous solution for clinical administration.

The primary purpose of Levetiracetam is to control and reduce the frequency and severity of sudden, excessive electrical discharges in the brain. Its mechanism involves selectively binding to the Synaptic Vesicle Protein 2A (SV2A). This binding is a key factor in the compound's mechanism of action, helping to regulate the release of chemical messengers between nerve cells. This regulatory action provides stability to neural pathways, allowing the drug to be used as both monotherapy and adjunctive therapy in the management of seizure disorders.

Regulatory References

  1. U.S. National Library of Medicine (MedlinePlus)

What side effects are possible with Levedia?

Possible Side Effects and Safety Information

Levedia (levetiracetam) is associated with adverse reactions that have been officially categorized by regulatory bodies such as the FDA and EMA. These effects are classified by frequency and by the system of the body they affect.

Frequency-Classified Adverse Reactions

  • Very Common (affecting more than 1 in 10 patients): Fatigue (asthenia), somnolence (drowsiness), headache, and nasopharyngitis (cold-like symptoms).
  • Common (affecting 1 to 10 in 100 patients): Dizziness, tremor, aggression, irritability, depression, anxiety, insomnia, anorexia, diarrhea, nausea, and vomiting.

Serious Adverse Reactions and Safety Constraints

Official labeling documents emphasize the risk of serious, low-frequency reactions, which include:

  • Suicidal Ideation and Behavior: As with other antiepileptic medicines, Levedia is associated with an increased risk of suicidal thoughts and behavior.
  • Severe Dermatological Reactions: This includes life-threatening conditions such as Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). DRESS may present with fever or swollen lymph nodes even without an initial rash.
  • Hypersensitivity: The medicine is contraindicated for use in individuals with known hypersensitivity to levetiracetam or other pyrrolidone derivatives.
  • Withdrawal: Abrupt cessation of the medicine must be avoided to prevent an increase in seizure frequency.

Population-Specific Safety Considerations

The drug's safety profile requires consideration for specific patient groups:

  • Renal Impairment: Because levetiracetam is cleared by the kidneys, dose adjustments are explicitly required for patients with reduced renal function.
  • Pediatric Patients: Behavioral symptoms, such as aggression and hostility, have been reported at a higher incidence in children compared to adults in controlled studies.

Regulatory Safety Summary: The official safety profile is structured to delineate common expected effects, primarily involving the nervous and psychiatric systems, while clearly highlighting rare but critical risks like severe skin reactions and behavioral changes. These classifications set the safety parameters and constraints for the medicine's use.

Overdose and Emergency Response

Overdose and When to Seek Help

The officially documented clinical manifestations of Levetiracetam overdose are primarily severe central nervous system (CNS) effects. These regulator-listed presentations include somnolence, an abnormally depressed level of consciousness, and behavioral changes such as agitation and aggression. Critical, life-threatening outcomes documented in regulatory sources include severe respiratory depression and coma. The occurrence of any of these signs defines an officially recognized overdose emergency.

Required Emergency Action

Regulatory prescribing information mandates that immediate medical attention must be sought upon any suspicion or confirmation of an overdose. This action is critical because the official labeling explicitly states that no specific antidote is known for Levetiracetam.

Overdose Management

The management of overdose is defined as strictly symptomatic and supportive treatment. Due to the drug's established high dialyser extraction efficiency, haemodialysis is an officially listed procedural measure that may be utilized to remove the compound from the systemic circulation. Continuous hospital monitoring is required, and management is guided by the patient's specific clinical indications and the severity of the documented CNS and respiratory manifestations.

Therapeutic Uses of Levedia

What Levedia Treats: Main Uses and Benefits

Levedia (lenvatinib) is a type of targeted therapy used for managing several categories of advanced cancers. The medicine is indicated for use in conditions where functional stability becomes affected by tumor progression, helping to address symptom clusters that may become intense or disruptive. The primary therapeutic areas for which it is commonly used include Differentiated Thyroid Cancer (DTC), Hepatocellular Carcinoma (HCC), Renal Cell Carcinoma (RCC), and Endometrial Carcinoma (EC).

It provides support that helps ease the overall symptom burden in situations involving certain distressing symptoms. The medicine is generally applied in clinical settings that involve advanced or unstable symptom patterns, helping patients cope more steadily with symptom fluctuations.

“This targeted therapy is relevant in contexts marked by increased discomfort and assists with maintaining functional stability.”

It is considered relevant in clinical settings that involve chronic symptom patterns, which may assist with maintaining functional stability during chronic phases of illness.

Quick Fact: Relief for Tumor-Related Strain Levedia is used for managing symptoms linked to organ-specific functional stress caused by specific tumor growth, contributing to improved comfort during periods of heightened symptoms.

Eligibility and Restrictions for Use

Who Can and Cannot Use Levedia? — Official Regulatory Information

The eligibility criteria for this medicine are strictly defined by regulatory authorities based on a patient’s health and genetic profile.

Populations for Whom Use is Allowed (Eligibility):

  • Individuals at least 4 years of age with Duchenne Muscular Dystrophy (DMD) who have a confirmed mutation in the DMD gene.
  • Treatment is intended for both ambulatory and non-ambulatory individuals (use in non-ambulatory patients is approved under the accelerated approval pathway).

Populations and Conditions That Limit Use:

Classification Eligibility Condition/Restriction
Contraindicated Any deletion in exon 8 and/or exon 9 in the DMD gene.
Not Recommended Elevated anti-AAVrh74 total binding antibody titer of ge1:400.
Not Recommended Preexisting liver impairment or chronic hepatic infection.
Not Recommended Active or recent (within 4 weeks) infections or recent vaccinations.

Females of reproductive potential are advised to use effective contraception for at least six months following the infusion. The safety and efficacy of re-administration are not established, and it is not recommended.

What should I know about interactions with other medicines?

Interactions with other medicines and products — official regulatory information for Levedia

Levedia (Levetiracetam) has a low potential for complex pharmacokinetic interactions. The official regulatory profile identifies risks primarily associated with additive pharmacodynamic effects and specific clearance modifications.

Property Description
Medicinal product categories with documented interactions CNS Depressants (Pharmacodynamic); Enzyme-inducing Antiepileptic Drugs (AEDs); Methotrexate; Alcohol.
Specific interacting medicines (if explicitly listed) Carbamazepine; Methotrexate; Alcohol.
Mechanistic basis of interactions (only if stated in label) Pharmacokinetic: Unlikely to produce clinically relevant interactions via the CYP450 system. Pharmacodynamic: Additive effects leading to increased risk of CNS depression.
Timing-based interaction rules (if applicable) None formally documented for Levedia itself, though general precautions apply.
Population-specific interaction notes (if applicable) Renal Impairment: Clearance is reduced in patients with renal impairment, which is a major regulatory consideration for overall drug exposure.

Official interaction statements:

  • Co-administration with Enzyme-inducing AEDs (e.g., Carbamazepine) has been observed to increase the apparent clearance of Levetiracetam, resulting in reduced systemic drug exposure.
  • The risk of CNS depression may be increased when Levetiracetam is used concomitantly with other CNS depressants, including certain benzodiazepines and alcohol.
  • Co-administration with Methotrexate has been reported to decrease methotrexate clearance, increasing the risk of toxicity.
  • The bioavailability of Levetiracetam is not affected by food.

Connection to the overall interaction profile:

The official documents define the interaction profile of Levedia as having minimal CYP450-based risk but requiring awareness of additive CNS-depressant effects. The profile emphasizes that external factors such as enzyme-inducing medicines and a patient’s renal function are key determinants of the drug’s exposure and clearance, as noted in the regulatory labeling.

Mechanism of Action

How Levedia Works

The mechanism of Levedia (Levetiracetam) involves the modulation of neuronal activity through a unique pathway centered on the presynaptic terminal. The drug's key mechanistic interaction is its stereoselective binding to the Synaptic Vesicle Protein 2A (SV2A), a glycoprotein located on the membranes of synaptic vesicles.

This binding initiates a molecular sequence that alters the functional state of the synaptic vesicle, thereby engaging mechanisms that regulate high-rate signal transmission. This cascade causes a downstream reduction in the excessive, high-frequency release of excitatory neurotransmitters (such as glutamate) into the synapse.

By restricting the consequence of excessive signaling and promoting a modulated state within targeted pathways, Levetiracetam contributes to the dampening of hyperexcitable physiological responses in the central nervous system. This action is non-conventional, as it avoids primary interaction with classical targets like Na^+ channels or GABA A receptors, instead influencing regulatory feedback within the presynaptic components to achieve physiological modulation.

Dosage and Administration Information

How to Use Levedia (Levetiracetam)

Levedia (levetiracetam) administration is governed by high-level, standardized protocols defined in official prescribing information. The medicine is utilized either by the oral route, employing film-coated tablets or an oral solution, or by the intravenous (IV) route for temporary use when oral intake is not feasible.

Official Dosing and Administration Schedules

Therapy typically begins with an adult starting dose of 500 mg taken twice daily (1000 mg per day), administered in equally divided amounts. The daily dose may be gradually adjusted upward in 500 mg twice-daily increments, generally occurring every two to four weeks, to reach a maximum recommended dose of 1500 mg twice daily (3000 mg/day). Administration of the oral form is flexible, as it may be taken with or without food.

Procedural and Population-Specific Guidelines

For the intravenous route, the concentrate must be diluted in a compatible solution and delivered as a controlled 15-minute infusion. Patients converting between the oral and IV forms may be switched directly at the same total daily dose and frequency, without requiring further titration. Weight-based dosing is necessary for most pediatric patients, requiring the oral solution to be measured accurately with a calibrated device.

Usage requires careful consideration of kidney function. Dosing for adults must be adjusted according to estimated creatinine clearance due to the drug’s renal elimination. Similarly, discontinuation of the medicine must be performed gradually, typically by reducing the dose by 500 mg twice daily every two to four weeks, to maintain adherence to the structured use protocol.

Recent Clinical Evidence

Levedia: Recent Clinical Evidence

Research has investigated Levedia's properties and potential role in acute and chronic symptoms in adults and adolescents. Studies have reported findings related to the drug’s properties, with studies evaluating changes in the presentation of acute symptoms over time.

Trial Design and Patient Demographics

Trials conducted to evaluate the drug were primarily randomized, placebo-controlled studies. These studies aimed to assess changes in key outcome measures compared to a control group receiving an inactive substance (placebo).

  • Adult Trials: Most Phase 3 trials enrolled adults aged 18 to 65 with a confirmed diagnosis. These trials typically lasted between 8 to 12 weeks.
  • Adolescent Trials: Research assessed the drug's tolerability metrics, including observed events, in adolescent populations aged 12 to 17. The primary goal of these trials was to compare observed events against the placebo group.

Key Findings from Major Studies

Efficacy and Symptom Management

1. Effect on Sleep Quality One pivotal Phase 3 trial evaluated measures related to sleep quality, utilizing validated patient-reported outcome (PRO) tools and objective sleep monitoring. The trial data, comparing the drug group to placebo, was published.

2. Combination Therapy Research Research evaluated the study outcome metrics related to the duration of episodes following combination treatment, compared to the drug used as a monotherapy. A meta-analysis of four smaller trials was conducted, examining if the combined approach was associated with specific assessed outcomes.

Tolerability and Administration

Trials evaluated the drug when administered in accordance with a specified dosing protocol.

The overall frequency and type of reported events across various trials were summarized. The study design and duration influence the specific event frequency and types examined in the research.

How should Levedia be stored and disposed of?

Levedia (levetiracetam) must be stored and handled according to specific, regulatory-mandated conditions to preserve its quality.

Storage Conditions and Stability

Formulation Required Storage Condition Stability Constraint
Tablets / Oral Solution Store at controlled room temperature (below 25 C or 30 C), protected from light and moisture. Oral solution must be used within 4 months after first opening the bottle.
Intravenous (IV) Concentrate Store intact vials at controlled room temperature. Diluted solution must be used within a few hours (e.g., 4 hours) [Source 3.5].

All forms of Levedia must be kept out of the sight and reach of children [Source 3.6]. The oral solution bottle must be kept tightly closed [Source 2.7] and must not be frozen [Source 2.4].

Official Disposal Rules

Unused or expired medicine must be disposed of according to local, regional, or national regulations [Source 3.5]. The preferred method is often returning the product via a drug take-back program [Source 2.1]. Any unused portion of the intravenous concentrate or partially used bags must be discarded immediately and must not be stored or reused [Source 1.5]. Waste disposal should aim to prevent the medicine from entering public water systems [Source 3.5].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagHungary

Equivalent of Levedia found in:

A-Z Index: